Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of SAB-176 in Healthy Subjects
NCT06435936Phase 1Active, not recruiting
- Sponsor
- SAB BIO
- Start
- Apr 2024
- Primary completion
- Feb 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SAB-176 in influenza (8 arms), sponsored by SAB BIO. Primary endpoints: Occurrence of solicited local and systemic adverse events at Day 29, Occurrence of IP-related unsolicited adverse events at Day 61 and 1 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
SAB-176
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06435936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06435936.